Potential and purported roles for chromium in insulin signaling: The search for the holy grail

The Nutritional Biochemistry of Chromium (III)

Volumn , Issue , 2007, Pages 139-160

  Vincent, John B ^a   Bennett, Randall ^a  

^a UNIVERSITY OF ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41849131188     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044453071-4/50008-4     Document Type: Chapter

References (85)

1. A.R. Saltiel and C.R. Kahn (2001) Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414 799-806.
2. B.J. Goldstein (2002) Protein-tyrosine phosphatases: Emerging targets for therapeutic inter-vention in type 2 diabetes and related states of insulin resistance. J. Clin. Endocrinol. Metab. 87 2474-2480.
3. L.L. Hopkins and K. Jr.Schwarz (1964) Chromium (III) binding to serum proteins, specifically siderophilin. Biochim. Biophys. Acta 90 484-491.
4. B.J. Clodfelder, R.G. Upchurch and J.B. Vincent (2004) A comparison of the insulin-sensitive transport of chromium in healthy and model diabetic rats. J. Inorg. Biochem. 98 522-533.
5. B.J. Clodfelder, J. Emamaullee, D.D. Hepburn, N.E. Chakov, H.S. Nettles and J.B. Vincent (2001) The trail of chromium (III) from the blood to the urine: The roles of transferrin and chromodulin. J. Biol. Inorg. Chem. 6 608-617.
6. B.J. Clodfelder and J.B. Vincent (2005) The time-dependent transport of chromium in adult rats from the bloodstream to the urine. J. Biol. Inorg. Chem. 10 383-393.
7. H.J. Dowling, E.G. Offenbacher and F.X. Pi-Sunyer (1990) Effects of plasma transferrin and albumin on the absorption of trivalent chromium. Nutr. Res. 10 1251-1260.
8. A. Yamamoto, O. Wada and T. Ono (1981) A low-molecular-weight, chromium-binding substance in mammals. Toxicol. Appl. Pharmacol. 59 515-523.
9. G.Y. Wu and O. Wada (1981) Studies on a specific chromium binding substance (a low-molecular-weight chromium binding substance) in urine. Jpn. J. Ind. Health 23 505-512.
10. O. Wada, S. Manabe, N. Yamaguchi, S. Ishikawa and H. Yanagisawa (1983) Low-molecular-weight, chromium-binding substance in rat lungs and its possible role in chromium movement. Ind. Health 21 35-41.
11. A. Yamamoto, O. Wada and T. Ono (1984) Distribution and chromium-binding capacity of a low-molecular-weight, chromium-binding substance in mice. J. Inorg. Biochem. 22 91-102.
12. A. Yamamoto, O. Wada and T. Ono (1987) Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. Eur. J. Biochem. 165 627-631.
13. C.M. Davis and J.B. Vincent (1997) Isolation and characterization of a biologically active form of chromium oligopeptide from bovine liver. Arch. Biochem. Biophys. 339 335-343.
14. K.H. Sumrall and J.B. Vincent (1997) Is glucose tolerance factor an artifact produced by acid hydrolysis of low-molecular-weight chromium-binding substance? Polyhedron 16 4171-4177.
15. O. Wada, G.Y. Wu, A. Yamamoto, S. Manabe and T. Ono (1983) Purification and chromium-excretory function of low-molecular-weight, chromium-binding substances from dog liver. Environ. Res. 32 228-239.
16. A. Yamamoto, O. Wada and H. Suzuki (1988) Purification and properties of biologically active chromium complex from bovine colostrum. J. Nutr. 118 39-45.
17. D. Dinakarpandian, V. Morrissette, S. Chaudhary, K. Amini, B. Bennett and H.J.D. Van Horn J.D. (2004) An informatics search for the low-molecular weight chromium-binding peptide. BMC Chemical Biology 4 2. 6769/4/2
18. J.B. Vincent, J. Hatfield and S. Burdette (2004) Characterizing chromium-containing oligopeptides. Abstracts of the 227th ACS National Meeting, Nanheim, CA March 28-April 1, 2004 CHED 381
19. K. Kurohara, Y. Matsuda, A. Nagabukuro, A. Tsuji, T. Amagasa and A. Fujisawa-Sehara (2000) Meltrin b (ADAM 19) gene: Cloning, mapping, and analysis of the regulatory region. Biochem. Biophys. Res. Commun. 270 522-527.
20. Y. Sun, J. Ramirez, S.A. Woski and J.B. Vincent (2000) The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LMWCr) and the transfer of chromium from transferrin and Cr (pic) 3. J. Biol. Inorg. Chem. 5 129-136.
21. L. Jacquamet, Y. Sun, J. Hatfield, W. Gu, S.P. Cramer, M.W. Crowder, G.A. Lorigan, J.B. Vincent and J-M. Latour (2003) Characterization of chromodulin by X-ray absorption and electron paramagnetic spectroscopies and magnetic susceptibility measurements. J. Am. Chem. Soc. 125 774-780.
22. A. Levina, R. Codd, C.T. Dillion and P.A. Lay (2003) Chromium in biology: Toxicology and nutritional aspects. Prog. Inorg. Chem. 51 145-644.
23. C.M. Davis and J.B. Vincent (1997) Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 36 4382-4385.
24. E. Gaggelli, F. Berti, N. D'Amelio, N. Gaggelli, G. Valensin, L. Bovalini, A. Paffetti and L. Trabalzini (2002) Metabolic pathways of carcinogenic chromium. Environ. Health Perspect. 110(Suppl. 5), 733-738.
25. A. Levina, L.B. Zhang and P.A. Lay (2003) Structure and reactivity of a chromium (V) glutathione complex. Inorg. Chem. 42 767-784.
26. A. Yamamoto, O. Wada and H. Suzuki (1987) Separation of biologically active chromium complex from cow colostrum. Tohoku J. Exp. Med. 152 211-219.
27. J.B. Vincent (1994) Relationship between glucose tolerance factor and low-molecular-weight chromium-binding substance. J. Nutr. 124 117-118.
28. A. Yamamoto, O. Wada and S. Manabe (1989) Evidence that chromium is an essential fac-tor for biological activity of low-molecular-weight Cr-binding substance. Biochem. Biophys. Res. Commun. 163 189-193.
29. C.M. Davis, K.H. Sumrall and J.B. Vincent (1996) The biologically active form of chromium may activate a membrane phosphotyrosine phopshatase (PTP). Biochemistry 35 12963-12969.
30. C.M. Davis, A.C. Royer and J.B. Vincent (1997) Synthetic multinuclear chromium assembly activates insulin receptor tyrosine kinase activity: Functional model for low-molecular-weight chromium-binding subst. Inorg. Chem. 36 5316-5320.
31. B.J. Goldstein, L. Zhu, R. Hager, A. Zilbering, Y. Sun and J.B. Vincent (2001) Enhancement of post-receptor insulin signaling by trivalent chromium in hepatoma cells is associated with differential inhibition of specific protein-tyrosine. J. Trace Elem. Exp. Med. 14 393-404.
32. I. Mulkani, A. Levina and P.A. Lay (2004) Biomimetic oxidation of chromium (III) : Does the antidiabetic activity of chromium (III) involve carcinogenic chromium (VI) ? Angew. Chem. Int. Ed. 43 4504-4507.
33. C.M. Davis and J.B. Vincent (1997) Chromium in carbohydrate and lipid metabolism. J. Biol. Inorg. Chem. 2 675-679.
34. J.B. Vincent (1999) Mechanism of action of chromium: low-molecular-weight chromium-binding substance. J. Am. Coll. Nutr. 18 6-12.
35. W.E. Meador, R.A. Means and F.A. Quiocho (1992) Target enzyme recognition: 2.4 A structure of a calmodulin-peptide complex. Science 257 1251-1255.
36. B.W. Morris, S. MacNeil, K. Stanley, T.A. Gray and R. Fraser (1993) The inter-relationship between insulin and chromium in hyperinsulinaemic euglycaemic clamps in healthy volunteers. J. Endocrin. 139 339-345.
37. R.A. Anderson, M.M. Polansky, N.A. Bryden, E.E. Roginski, K.Y. Patterson, C. Veillon and W. Glinsmann (1982) Urinary chromium excretion of human subjects: Effects of chromium supplementation and glucose loading. Am. J. Clin. Nutr. 36 1184-1193.
38. R.A. Anderson, M.M. Polansky, N.A. Bryden, E.E. Roginski, K.Y. Patterson and D.C. Reamer (1982) Effect of exercise (running) on serum glucose, insulin, glucagons, and chromium excretion. Diabetes 31 212-216.
39. A.S. Kozlovsky, P.B. Moser, S. Reisner and R.A. Anderson (1986) Effects of diets high in simple sugars on urinary chromium losses. Metabolism 35 515-518.
40. R.A. Anderson, N.A. Bryden, M.M. Polansky and S. Reiser (1990) Urinary chromium excretion and insulinogenic properties of carbohydrates. Am. J. Clin. Nutr. 51 864-868.
41. B.M. Morris, A. Blumsohn, S. MacNeil and T.A. Gray (1992) The trace element chromium-A role in glucose homeostasis. Am. J. Clin. Nutr. 55 989-991.
42. B.M. Morris, H. Griffiths and G.J. Kemp (1988) Effect of glucose loading on concentra-tions of chromium in plasma and urine of healthy adults. Clin. Chem. 34 1114-1116.
43. J. Vincent (2000) The biochemistry of chromium. J. Nutr. 130 715-718.
44. Y. Sun, K. Mallya, J. Ramirez and J.B. Vincent (1999) The biomimetic [Cr 3O (O 2CCH 2CH3) 6 (H 2O) 3] + decreases plasma cholesterol and triglycerides in rats: towards chromium-containing t. J. Biol. Inorg. Chem. 4 838-845.
45. R.D. Cannon and R.P. White (1988) Chemical and physical properties of triangular bridged metal complexes. Prog. Inorg. Chem 36 195-297.
46. M. Nagi, A. Harton, S. Donald, Y.S. Lee, M. Sabat, C.J. O'Connor and J.B. Vincent (1995) An unsymmetric trinuclear chromium (III) oxo carboxylate assembly: Structure and characterization of Cr 3O (O 2CPh) 4 (8-hqn) 3· 1.25CH 2Cl. Inorg. Chem. 34 3813-3820.
47. A. Harton, K. Terrell, J.C. Huffman, C. MacDonald, A. Beatty, S. Li, C. O'Connor and J.B. Vincent (1997) Synthesis and characterization of novel oxo-bridged dinuclear and hydroxo-bridged trinuclear chromium (III) assemblies. Inorg. Chem. 36 4875-4882.
48. A. Bino, R. Chayat, E. Pedersen and A. Schneider (1991) A new tetranuclear chromium (III) complex with a [Cr 4O 2] core: synthesis, structure, and magnetic properties of [Cr 4O 2 (O 2CCH 3) 7 (bpy) 2]PF 6 (bpy = 2,2'-bipyridine). Inorg. Chem. 30 856-858.
49. S. Donald, K. Terrell, J.B. Vincent and K.D. Robinson (1995) Modelling chromium biochemistry: Synthesis and characterization of [NEt 3H][Cr (III) 4O 2 (O 2CPh) 7 (pic) 2]CH 2Cl 2 (Hpic = Picol. Polyhedron 14 971-976.
50. T. Ellis, M. Glass, A. Harton, K. Folting, J.C. Huffman and J.B. Vincent (1994) Synthetic models for low-molecular-weight chromium-binding substance: Synthesis and characteriza-tion of oxo-bridged tetranuclear chromium (III) assemblies. Inorg. Chem. 33 5522-5527.
51. J.K. Speetjens, A. Parand, M.W. Crowder and J.B. Vincent (1999) Low-molecular-weight chromium-binding substance and biomimetic [Cr 3O (O 2CH 2CH 3) 6 (H 2O) 3] + do not cleave DNA under physiologically-relevant conditions. Polyhedron 18 2617-2624.
52. R.A. Anderson, N.A. Bryden and M.M. Polansky (1997) Lack of toxicity of chromium chloride and chromium picolinate. J. Am. Coll. Nutr. 16 273-279.
53. B.J. Clodfelder, B.M. Gullick, H.C. Lukaski, Y. Neggers and J.B. Vincent (2005) Oral administration of [Cr 3O (O 2CH 2CH 3) 6 (H 2O) 3] + increases insulin sensitivity and improves blood plasma variables in healthy and type 2 diabetic rats. J. Biol. Inorg. Chem. 10 119-130.
54. B. Debski, Z. Krejpcio, T. Kuryl, R. Wojciak and M. Lipko (2004) Biomimetic chromium (III) complex and fructan supplementation affect insulin and membrane glucose transport in rats. J. Trace Elem Exp. Med. 17 206-207.
55. Z. Krejpcio, B. Debski, R. Wojciak, T. Kuryl and M. Tubacka (2004) Biomimetic chromium (III) complex and fructan supplementation improve blood variables in STZ-induced diabetic rats. J. Trace Elem Exp. Med. 17 207-208.
56. A.A. Shute and J.B. Vincent (2001) The stability of the biomimetic cation triaqua-μ-oxohexapropionatotrichromium (III) in vivo in rats. Polyhedron 20 2241-2252.
57. A.A. Shute and J.B. Vincent (2002) The fate of the biomimetic cation triaqua-μ-oxohexapropionatotrichromium (III) in rats. J. Inorg. Biochem. 89 272-278.
58. B.J. Clodfelder, C. Chang and J.B. Vincent (2004) Absorption of the biomimetic cation triqua-μ 3-oxo-μ-hexapropionatotrichromium (III) in rats. Biol Trace Elem. Res. 98 522-533.
59. W.T. Cefalu, J.M. Martin, D. Wachtel, X.H. Zhang and Z.Q. Wang (2003) Chromium picolinate supplementation increases insulin-stimulated Akt phosphorylation in vivo in skeletal muscle from subjects with type 2 diabetes. 18th International Diabetes Federation Congress August 24–29, 2003, Paris —France Abstract 154
60. W.T. Cefalu (2003) Mechanism of action of chromium: Cellular signaling. presentation at Chromium in Health and Disease, A CADRE Research Summit April 1–2, 2003, Boston, MA
61. W.T. Cefalu, Z.Q. Wang, X.H. Zhang, L.C. Baldor and J.C. Russell (2002) Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skele-tal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA) rat. J. Nutr. 132 1107-1114.
62. X. Yang, K. Palanichamy, A.C. Ontko, M.N.A. Rao, C.X. Fanf, J. Ren and N. Sreejayan (2005) A newly synthetic chromium complex-chromium (phenylalanine) 3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett. 579 1458-1464.
63. A. Levina and P.A. Lay (2005) Mechanistic studies of relevance to the biological activities of chromium. Coord. Chem. Rev. 249 281-298.
64. E. Kim and K.J. Na (1991) Effect of sodium dichromate on carbohydrate metabolism. Toxicol. Appl. Pharmacol. 110 251-258.
65. Y. Goto and K. Kida (1995) Insulin-like action of chromate on glucose transport in isolated rat adipocytes. Jpn. J. Pharmacol. 67 365-368.
66. E.J. Yurkow and G. Kim (1995) Effects of chromium on basal and insulin-induced tyrosine phosphorylation in H4 hepatoma cells: comparison with phorbol-12-myristate-13-acetate and sodium ort. Mol. Pharmacol. 47 686-695.
67. G. Kim and E.J. Yurkow (1996) Chromium induces a persistent activiation of mitogen-activated protein kinases by a redox-sensitive mechanism in H4 rat hepatoma cells. Cancer Res. 56 2045-2051.
68. L. Yang, D.C. Crans, V.G. Yuen, J. McNeill and G.R. Willsky (2000) Chemistry and insulin-like properties of chromium 2,6-pyridinedicarboxylate complexes. Abstracts of Papers — American Chemical Society 220th, 2000 INOR-047
69. K.H. Thompson, J. Chiles, V.G. Yuen, J. Tse, J.H. McNeill and C. Orvig (2004) Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes. J. Inorg. Biochem. 98 683-690. and references therein
70. K.G. Peters, M.G. Davis, B.W. Howard, M. Pokross, V. Rastogi, C. Diven, K.D. Greis, E. Eby-Wilkens, M. Maier, A. Evdokimov, S. Soper and F. Genbauffe (2003) Mechanism of insulin sensization by BMOV (bis maltolato oxo vanadium) ; unligated vanadium (VO 4) as the active component. J. Inorg. Biochem. 96 321-330.
71. A.B. Goldfine, M.E. Patti, L. Zuberi, B.J. Goldstein, R. LeBlanc, E.J. Landaker, Z.Y. Jiang, G.R. Willsky and C.R. Kahn (2000) Metabolic effects of vanadyl sulfate in humans with non-insulin dependent diabetes mellitus: in vivo and in vitro studies. Metabolism 49 400-410.
72. B. Lu, D. Ennis, R. Lai, E. Bogdanovic, I.G. Nikolov, L. Salamon, C. Fantus, H. Le-Tien and I.G. Fantus (2001) Enhanced sensitivity of insulin-resistant adipocytes to vanadate is associated with oxidative stress and decreased reduction of vanadate (+5) and vanadyl (+4). J. Biol. Chem. 276 35589-35598.
73. K.L. Olin, D.M. Stearns, W.H. Armstrong and C.L. Keen (1994) Comparative reten-tion/absorption of chromium ( 51Cr) from 51Cr chloride, 51Cr nicotinate and 51Cr picolinate in a rat model. Trace Elem. Electrolytes 11 182-186.
74. R.A. Anderson, N.A. Bryden, M.M. Polansky and K. Gautschi (1996) Dietary chromium effects on tissue chromium concentrations and chromium absorption in rats. J. Trace Elem. Exp. Med. 9 11-25.
75. B.J. Goldstein, M. Kalyankar and X. Wu (2005) Redox paradox: Insulin action is facili-tated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 54 311-321.
76. S.K. Jain and K. Kannan (2001) Chromium chloride inhibits oxidative stress and TNF-α secretion caused by exposure to high glucose in cultured U937 monocytes. Biochem. Biophys. Res. Commun. 289 687-691.
77. T. Kordella (2004) Chromium:Can it help kids with type 2? Diabetes Forecast 57 83-85.
78. S.K. Jain, K. Rogier, L. Prouty and S.K. Jain (2004) Protective effects of 17β-estradiol and trivalent chromium on interleukin-6 secretion, oxidative stress, and adhesion of monocytes: Relevance to heart disease in postmenopausal women. Free Radic. Biol. Med. 37 1730-1735.
79. I. Catelas, A. Petit, D.J. Zukor, J. Antoniou and O.L. Huk (2002) TNF-α secretion and machrophage mortality induced by cobalt and chromium ion in in vitro-Qualitative analysis of apoptosis. Biomaterials 24 383-391.
80. L. Luo, A. Petit, J. Antoniou, D.J. Zukor, O.L. Huk, R.C.W. Liu, F.M. Winnik and F. Mwale (2005) Effect of cobalt and chromium ions on MMP-1, TIMP-1, and TNF-α gene expression in human U937 macrophages: A role for tyrosine kinases. Biomaterials 26 5587-5593.
81. R.A. Anderson (1989) Essentiality of chromium in humans. Sci. Total Environ. 86 75-81.
82. R.A. Anderson, M.M. Polansky, N.A. Bryden, S.J. Bhathena and J.J. Canary (1987) Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia. Metabolism 36 351-355.
83. S. Yoshimoto, K. Sakamoto, I. Wakabayashi and H. Masui (1992) Effect of chromium on glucose tolerance in stroke-prone spontaneously hypertensive rats with streptozotocin-induced diabetes. Metabolism 41 636-642.
84. J.B. Vincent (2001) The bioinorganic chemistry of chromium (III). Polyhedron 20 1-26.
85. H. Wang, A. Kruszewski and D.L. Brautigan (2005) Cellular chromium enhances activa-tion of insulin receptor kinase. Biochemistry 44